“Dinutuximab’s Promise in Neuroblastoma Treatment: Future Research Directions”

https://pubmed.ncbi.nlm.nih.gov/38116487

Dinutuximab, a GD2-targeting antibody, shows promise in improving survival and prolonging remission in neuroblastoma patients, but further research is needed to optimize its use and manage associated toxicities.